Why the study?
Do platelets from patients with diabetes mellitus have decreased sensitivity to prostacyclin compared to healthy controls?
Do platelets from patients with diabetes mellitus have decreased sensitivity to prostacyclin compared to healthy controls?
Platelets from patients with diabetes mellitus show decreased sensitivity to prostacyclin, which may contribute to hypercoagulability and diabetic microangiopathy.
Answers are grounded in this paper and cite their sources.
Decreased platelet prostacyclin sensitivity in diabetes may promote hypercoagulability; hypothesis-generating from Level 4 data and needs prospective confirmation.
In order to ascertain the platelet sensitivity to prostacyclin (PGI2) in patients with diabetes mellitus, we determined the percentage inhibition of platelet aggregation and platelet ATP secretion following PGI2 addition in an in vitro system. The percentage inhibition of platelet aggregation caused by PGI2 in final concentration of 1.25, 2.5, or 5.0 ng/ml was significantly lower in diabetics than in healthy controls. That of platelet ATP secretion by 1.25 or 2.5 ng/ml of PGI2 was also significantly lower in diabetics. These data suggested that in patients with diabetes mellitus, the decreased sensitivity of platelets to PGI2 will bring about hypercoagulability and may become one of the risk factors of diabetic microangiopathy in cooperation with lowered vascular PGI2 generation.
No takes yet. Share an insight, caveat, or question.
Akai et al. (1983) studied Diabetes Mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: